Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
Authors
Keywords
-
Journal
BMC Medical Genetics
Volume 19, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-17
DOI
10.1186/s12881-018-0703-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
- (2018) Emmanuel S. Antonarakis et al. EUROPEAN UROLOGY
- PARP inhibitors for homologous recombination-deficient prostate cancer
- (2018) Eric S. Christenson et al. EXPERT OPINION ON EMERGING DRUGS
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
- (2018) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
- (2017) David Quigley et al. Cancer Discovery
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- Defective DNA repair mechanisms in prostate cancer: impact of olaparib
- (2017) Francesca De Felice et al. Drug Design Development and Therapy
- Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and aBRCAmutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
- (2016) Ursula A. Matulonis et al. CANCER
- PARP inhibitors: A new era of targeted therapy
- (2015) Shifalika Tangutoori et al. MATURITAS
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
- (2015) Matthew J. Niederst et al. Nature Communications
- Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
- (2013) Julio Morales et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- Mechanisms of resistance to therapies targeting BRCA-mutant cancers
- (2013) Christopher J Lord et al. NATURE MEDICINE
- Resistance to PARP-Inhibitors in Cancer Therapy
- (2013) Alicia Montoni et al. Frontiers in Pharmacology
- BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
- (2011) Z Kote-Jarai et al. BRITISH JOURNAL OF CANCER
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- (2010) Peter Bouwman et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Rapid progression of prostate cancer in men with a BRCA2 mutation
- (2008) S A Narod et al. BRITISH JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started